IGM Biosciences
IgM antibody platform with 10 binding sites for cancer immunotherapy
- Sector
- Biotech
- Headquarters
- MOUNTAIN VIEW, CA
- Latest Form D
- $22.5M, Jul 2023
- Total capital
- $23.8M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $23.8M
- 2 Form D · last Jul 2023
- 40 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 12
- 28 pending · first 2021
- Rank in peer group#81 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$22.5M
- Private capital raisedForm D · SEC · 1st filing$1.3M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#81 · top 6%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Bruce A KeytExecutive OfficerNamed in SEC Form D filings
- Chris H. TakimotoExecutive OfficerNamed in SEC Form D filings
- Christina Teng TopsoeDirectorNamed in SEC Form D filings
- Felix J. BakerDirectorNamed in SEC Form D filings
- Fred M. SchwarzerExecutive Officer, DirectorNamed in SEC Form D filings
- George A GauthierExecutive OfficerNamed in SEC Form D filings
Show all 14 people
- Jakob Haldor TopsoeDirectorNamed in SEC Form D filings
- Julie J. HambletonDirectorNamed in SEC Form D filings
- Lisa L. DeckerExecutive OfficerNamed in SEC Form D filings
- Michael J. LeeDirectorNamed in SEC Form D filings
- Michael J. LobergDirectorNamed in SEC Form D filings
- Misbah A TahirExecutive OfficerNamed in SEC Form D filings
- M. Kathleen J. BehrensDirectorNamed in SEC Form D filings
- William J. StrohlDirectorNamed in SEC Form D filings
What it has protected
USPTO · 12 granted of 40- GrantedIgm Fc And J-chain Mutations That Affect Igm Serum Half-lifeUSPTOUS 12,649,791
- PendingMethods Of Treating Autoimmune Disorders Using Multimeric ANTI-CD38/ANTI-CD3 AntibodiesUSPTOApplication 19106184
- GrantedBinding Molecules With Modified J-chainUSPTOUS 12,486,336
Show all 40 patent records
- Igm Fc And J-chain Mutations That Affect Igm Serum Half-lifeJun 9, 2026 · US 12,649,791Granted
- Methods Of Treating Autoimmune Disorders Using Multimeric ANTI-CD38/ANTI-CD3 AntibodiesMar 12, 2026 · Application 19106184Pending
- Binding Molecules With Modified J-chainDec 2, 2025 · US 12,486,336Granted
- ANTI-CD38 Binding Molecules And Uses ThereofFeb 13, 2025 · Application 18719191Pending
- ANTI-CD123 Binding Molecules And Uses ThereofMar 7, 2024 · Application 18261145Pending
- ANTI-PD-L1 AntibodiesJan 4, 2024 · Application 18463194Pending
- Uses Of Effector Cell Engaging Molecules With Moieties Of Differing PotenciesJan 4, 2024 · Application 18252759Pending
- Modified J-chainSep 7, 2023 · Application 18052388Pending
- PD-1 Agonist Multimeric Binding MoleculesJul 6, 2023 · Application 17996760Pending
- Immunostimulatory Multimeric Binding MoleculesJun 29, 2023 · Application 17635078Pending
- Tumor Necrosis Factor (tnf) Superfamily Receptor Igm Antibodies And Uses ThereofJun 29, 2023 · Application 18055340Pending
- Use Of A Multimeric ANTI-DR5 Binding Molecule In Combination With A Cancer Therapy For Treating CancerJun 8, 2023 · Application 17998307Pending
- Binding Molecules With Modified J-chainMay 2, 2023 · US 11,639,389Granted
- Highly Sialylated Multimeric Binding MoleculesMar 9, 2023 · Application 17758207Pending
- Multimeric Coronavirus Binding Molecules And Uses ThereofFeb 23, 2023 · Application 17386397Pending
- Polynucleotides Encoding Death Domain-containing RECEPTOR-5 (DR5) Binding MoleculesFeb 14, 2023 · US 11,578,131Granted
- Modified J-chainJan 17, 2023 · US 11,555,075Granted
- Binding Molecules With Modified J-chainJan 3, 2023 · US 11,542,342Granted
- Multi-valent Hepatitis B Virus Antigen Binding Molecules And Uses ThereofDec 27, 2022 · US 11,535,664Granted
- Multimeric Coronavirus Binding Molecules And Uses ThereofDec 22, 2022 · Application 17812614Pending
- Multimeric Antibodies With Enhanced Selectivity For Cells With High Target DensityNov 24, 2022 · Application 17761428Pending
- Modified Human Igm Constant Regions For Modulation Of Complement-dependent Cytolysis Effector FunctionOct 27, 2022 · Application 17806339Pending
- Igm GlycovariantsSep 29, 2022 · Application 17637349Pending
- Multimeric Bispecific ANTI-CD123 Binding Molecules And Uses ThereofSep 15, 2022 · Application 17635490Pending
- Multimeric SARS-COV-2 Binding Molecules And Uses ThereofAug 25, 2022 · Application 17671837Pending
- Modified Human Igm Constant Regions For Modulation Of Complement-dependent Cytolysis Effector FunctionAug 2, 2022 · US 11,401,337Granted
- Multimeric Gitr Binding Molecules And Uses ThereofJun 9, 2022 · Application 17680026Pending
- Multimeric OX40 Binding Molecules And Uses ThereofJun 2, 2022 · Application 17673864Pending
- Anti-gitr Antigen-binding Domains And Uses ThereofApr 7, 2022 · Application 17427882Pending
- Multimeric CD40 Binding Molecules And Uses ThereofApr 7, 2022 · Application 17555282Pending
- Multimeric CD137/4-1BB Binding Molecules And Uses ThereofDec 16, 2021 · Application 17445278Pending
- MULTIVALENT IgM- AND IgA-Fc-BASED BINDING MOLECULESDec 9, 2021 · Application 17287828Pending
- Multi-valent Human Immunodeficiency Virus Antigen Binding Molecules And Uses ThereofDec 7, 2021 · US 11,192,941Granted
- ANTI-PD-L1 AntibodiesJun 3, 2021 · Application 17172790Pending
- Modified J-chainApr 13, 2021 · US 10,975,147Granted
- IgM Fc AND J-CHAIN MUTATIONS THAT AFFECT IgM SERUM HALF-LIFEMar 25, 2021 · Application 17110550Pending
- ANTI-PD-L1 AntibodiesMar 23, 2021 · US 10,954,302Granted
- CD20 Binding Molecules And Uses ThereofFeb 4, 2021 · Application 16938066Pending
- IgM Fc AND J-CHAIN MUTATIONS THAT AFFECT IgM SERUM HALF-LIFEJan 26, 2021 · US 10,899,835Granted
- Use Of A Multimeric ANTI-DR5 Binding Molecule In Combination With A Chemotherapeutic Agent For Treating CancerDec 17, 2020 · Application 16975438Pending
Related companies, and why
- COARE HOLDINGS INCSimilar federal contract value in Biotech · null in contracts
- Reservoir Neuroscience, Inc.Similar federal contract value in Biotech · null in contracts
- Carmot Therapeutics Inc.Similar federal contract value in Biotech · null in contracts
- REVOPSIS THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
- Elevian, Inc.Similar federal contract value in Biotech · null in contracts
- Momentum Superior Holdings, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .